Navigation Links
Boehringer Ingelheim to present new data at ASCO annual meeting regarding its investigational compound afatinib in EGFR-mutation positive patients with advanced NSCLC
Date:5/25/2011

RIDGEFIELD, Conn., May 25 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. will present new phase Ib data at the 2011 American Society of Clinical Oncology (ASCO) annual meeting in Chicago (June 3-7) that indicates combining its investigational therapy afatinib (BIBW 2992) with cetuximab at the maximum tested dose controlled disease in all (n=22) treated epidermal growth factor receptor (EGFR)-mutation positive patients with non-small cell lung cancer (NSCLC) who developed acquired resistance to treatment with a reversible EGFR tyrosine kinase inhibitor (TKI). Researchers observed a tumor size reduction of up to 76 percent over a treatment period of up to five months.(1) The most common drug-related adverse events were rash and diarrhea, with three patients (11.5%) experiencing Grade 3 rash. Afatinib is an orally-administered irreversible inhibitor of the erbB family of receptor tyrosine kinases, specifically EGFR and HER2.  It is in late-stage development in advanced NSCLC and breast cancer.

Boehringer Ingelheim and QIAGEN are pleased that ASCO and the National Comprehensive Cancer Network (NCCN), two leading oncology organizations, recently recommended EGFR mutation testing for patients with metastatic or recurrent NSCLC.  These recommendations underscore the importance of genetic tumor testing to predict patient response to certain treatments, enabling personalized healthcare.  Boehringer Ingelheim has partnered with QIAGEN to develop a real-time polymerase chain reaction assay (real-time PCR) companion diagnostic test for afatinib that, if approved, could help physicians identify which patients may benefit from EGFR-targeted therapies.

"The ASCO and NCCN EGFR mutation testing recommendations reinforce the importance of identifying the appropriate NSCLC patients for clinical trials," said Christopher Corsico, M.D., M.P.H., Senior Vice President, Medicine and Regulatory, Boehringer Ingelheim Pharmaceuticals, Inc. "
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune(R) (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients
2. Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study
3. Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009
4. Boehringer Ingelheim Unveils Diabetes Pipeline
5. Boehringer Ingelheim Animal Health Closes Deal to Acquire a Significant Portion of the Fort Dodge Animal Health Business From Pfizer
6. Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile
7. New Boehringer Ingelheim Science Quest Mobile Laboratory Brings Hands-On Science Education to Priority Connecticut Elementary Schools
8. Boehringer Ingelheim Affirms Safety of Telmisartan With an Analysis of 50,000 Patients and Strongly Disagrees With the Publication of Sipahi et al in Lancet Oncology June 2010
9. -- Neurocrine Announces a Second Corporate Collaboration Within Twenty-Four Hours -- Neurocrine Biosciences Announces a Worldwide Collaboration With Boehringer Ingelheim to Research and Develop GPR119 Agonists for Type II Diabetes
10. Boehringer Ingelheim Announces Pivotal Phase III Data Showing Linagliptin Reduced Blood Sugar Compared to Placebo in People With Type 2 Diabetes
11. Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... , May 21, 2013 STAAR Surgical Company ... and marketer of minimally invasive ophthalmic products, today announced ... to review the Company,s recent financial results and business ... Surgical will present at the 38 th Annual ... at the Westin Waterfront Hotel on Wednesday, ...
(Date:5/20/2013)... 2013  Volcano Corporation (NASDAQ: VOLC ) ... tools designed to enhance the diagnosis and treatment of ... highlight its efforts to expand research and innovation surrounding ... and iFR ® (Instant Wave-Free Ratio™) 1 ... at EuroPCR 2013 in Paris . ...
(Date:5/20/2013)... May 20, 2013 The Board of ... companies include OMNIlife science®, Inc., Enztec, Ltd., and Praxim, ... Board.  Guy Mayer , an ... of the Board of Directors and David Johnson, an ... director. Before joining OSI as Board ...
Breaking Medicine Technology:STAAR Surgical To Present At Upcoming Investor Conferences 2Volcano to Highlight its Physiology Expansion Efforts at EuroPCR 2013 2Volcano to Highlight its Physiology Expansion Efforts at EuroPCR 2013 3Volcano to Highlight its Physiology Expansion Efforts at EuroPCR 2013 4Orthopaedic Synergy, Inc. Announces Key Additions to the Board of Directors 2Orthopaedic Synergy, Inc. Announces Key Additions to the Board of Directors 3
... The Female Health Company (NASDAQ-CM: FHCO) today announced ... Comercio (Semina), was successful in a public tender to ... to 20 million FC2 Female Condoms.  The contract is ... will be determined at the Ministry of Health,s discretion. ...
... 6, 2011 Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ... Financial Officer, August J. Moretti will present during the MDB ... Tuesday, May 10, 2011 at 10:00 a.m. Eastern Time.  The ... To access the presentation via the Web, please go ...
Cached Medicine Technology:The Female Health Company's Brazilian Distributor, Semina, Awarded Contract For Up To 20 Million FC2 Female Condoms 2The Female Health Company's Brazilian Distributor, Semina, Awarded Contract For Up To 20 Million FC2 Female Condoms 3Alexza to Present at the MDB Bright Lights Conference 2011 2Alexza to Present at the MDB Bright Lights Conference 2011 3
(Date:5/21/2013)... An attack on glioblastoma brain tumor cells that ... an early study to establish the proper dose level, ... developed at Duke and tested in an ongoing phase ... have an abundance of receptors that work like magnets ... cells. , The investigational therapy, known as PVSRIPO, ...
(Date:5/21/2013)... Adeptia, a leading provider of innovative cloud ... is the featured company in an impact report written ... “Adeptia Bets on Converged Cloud Integration and Process-Orchestration Suites,” ... products, pricing, customers and competition. , “For ... integration and process orchestration, especially when price, ease of ...
(Date:5/21/2013)... HealthDay Reporter , , TUESDAY, May 21 (HealthDay News) -- ... some of the changes brought about by the disorder ... New research has found that people with diabetes who ... risk of having a severe low blood sugar (hypoglycemia) ... people with diabetes who aren,t depressed. "Depression ...
(Date:5/21/2013)... Grapefruits have long been known for their ... how medical therapies like anti-cancer drugs are delivered ... researchers have uncovered how to create nanoparticles using ... how to use them as drug delivery vehicles. ... Ph.D., and their team today (May 21, 2013), ...
(Date:5/21/2013)... May 21, 2013 Benefit Express Services, ... medium, and small organizations, will be hosting a free ... team from Findley Davies. The presentation will focus on ... in compliance with new Health Care Reform Requirements. The ... employees. , “Benefit Express regularly hosts free educational ...
Breaking Medicine News(10 mins):Health News:Poliovirus vaccine trial shows early promise for recurrent glioblastoma 2Health News:Adeptia Featured in Recent 451 Research Impact Report 2Health News:Depression May Raise Low Blood Sugar Risk in Diabetics 2Health News:Depression May Raise Low Blood Sugar Risk in Diabetics 3Health News:UofL scientists uncover how grapefruits provide a secret weapon in medical drug delivery 2Health News:Benefit Express to Host Workplace Wellness Webinar 2
... and burying people who have died of HIV/AIDS in the ... living with the virus. ,"It is indeed shocking to ... dead body of a person who has died of HIV/AIDS ... the Mizoram People Living with HIV/AIDS Society, told IANS. ...
... by a whopping 25 percent annually to fetch India ... Minister Ambika Soni said Wednesday.// ,"The sector has ... foreign patients, we estimate that the country may fetch ... the "Incredible India: The Global Healthcare Destination" brochure. ...
... attack, New York City's Health Department yesterday issued long-awaited ... It comprises medical advice that is supposed to be ... scattered across the United States. ,The guidelines ... illness resulting from 9/11 experiences was previously given by ...
... cases in Africa as of last year hover around ... Nations //.The World Health Organization has suggested an intelligent ... ,The WHO has advised that the ... Africa could be used to give an impetus to ...
... Science (RIMS) here is battling for life after doctors gave her ... to RIMS for a surgery, received B+ blood instead of her ... next 48 hours are critical for her. ,She was ... ago. Her condition worsened when she was given the wrong blood, ...
... pill according to European researchers. The latest study supports ... allergen tablet.// Hay fever and other allergies have long ... result of the immune system reacting to a normally ... is supposed to enhance tolerance of the immune system ...
Cached Medicine News:Health News:Strange Burial Practice Followed for People Affected by HIV/AIDS 2Health News:Medical Tourism can Fetch Rs.100 bn Annually by 2012 2Health News:Medical Tourism can Fetch Rs.100 bn Annually by 2012 3Health News:Medical Guidelines to treat 9/11-related illness 2
Empore Sealing Tape Pads are ideal for covering a 96 well plate during storage or transfer to another work station. Not intended for use with auto-injectors....
... is a quick and effective means to seal ... tubes. The compliant inner layer is designed to ... minimizes the risk of aerosol formation and cross-contamination ... use with fewer than 96 wells, and a ...
OptiTape individual sheets. Optically clear sealing tape for OmniUltra PCR plates. 100 pk....
OptiTape - Optically Clear sealing tape for OmniUltra PCR plates plus universal dispenser. 250 sheets....
Medicine Products: